Enterprise dynamics
JNJ
An earthquake of magnitude 6.8 occurred in Luding County, Ganzi Tibetan Autonomous Prefecture, Sichuan Province, and people in the affected areas urgently needed rescue and medical treatment. After the earthquake, Johnson & Johnson China paid close attention to the progress of the disaster and the medical needs from the front line of disaster relief, and started the natural disaster response mechanism at the first time. Johnson & Johnson China announced that it will donate RMB 1 million to the China Red Cross Foundation to support the repair and reconstruction of many Pok Oi health centers and hospitals in the disaster-stricken areas.
Pfizer
Sponsored by Pfizer, the "Atopic Dermatitis Summit Forum" was successfully held in Beijing. In the form of "online+offline", the conference brought together academic leaders of dermatology in nine cities, including Beijing, Shanghai, Chongqing, Shenzhen, Nanjing, Qingdao, Wuhan, Kunming and Taiyuan, to discuss new ideas of long-term standardized treatment of atopic dermatitis and open a "comfortable new journey" for patients with atopic dermatitis in China.
Anjin
China Station of Amgen Biotechnology Experience (ABE) established by Amgen Foundation was officially launched. This is the re-cooperation between Amgen Foundation and Tsinghua University, a well-known university in China. This year, 47 middle school students were selected to carry out the classic course "Foundations of Biotechnology Labs" of ABE project in Yunnan and Beijing, respectively, so that students can use research-level biotechnology equipment and experience experiments with their own hands. Six middle school teachers also participated. Since its establishment in 1990, the ABE project has expanded to the whole world, with 24 sites set up. It is expected that by 2023, the number of middle school students participating in the project will reach nearly 1 million.
Danach
The China International Fair for Trade in Services-Beijing "Two Zones" Construction and Enterprise Globalization Forum (CCG 9th China Enterprise Globalization Forum) jointly organized by the Globalization Think Tank (CCG) and Beijing "Two Zones" Office was held in the National Convention Center and Shougang Park. Wei Chunyan, executive director of CCG and vice president of government affairs in China, Danaher, delivered a speech at the theme roundtable forum. "The development of multinational companies cannot be separated from a stable economy, and a stable economy cannot be separated from industrial innovation and upgrading." Wei Chunyan said, "Danaher is optimistic about the growth potential and innovation ability of the China market, and will continue to increase the resource input in the China market, and help the upgrading of the big health industry and economic development through the promotion of Danaher’s localization strategy of" creating China ". "
Kracie Pharmaceuticals of Japan
Kracie Pharmaceutical, a subsidiary of Kracie Holdings, will build a new factory in China to manufacture Chinese medicine raw materials. This will be the company’s second factory in China. Together with the existing factories at home and abroad in Japan, the production capacity will be expanded to about 1.4 times, and the storage capacity of raw herbs will be expanded to more than 3 times. Chinese prescription medicine is made of effective components extracted from raw materials such as plants and fossils. The new factory is located in Weihai City, Shandong Province, and will be put into use in the autumn of 2023. It will be responsible for the process of crushing raw herbs and manufacturing extract powder, and the final product will be made in Japan.
Product/R&D trends
diabetes
Lilly’s application for the marketing of Mounjaro(tirzepatide), a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide -1(GLP-1) receptor, was accepted to improve the blood sugar control of adult type 2 patients. Mounjaro is the first new type of diabetes drug in recent 10 years.
Medical instruments
The bedside lower limb rehabilitation system of Eston Medical was approved by Jiangsu Food and Drug Administration and obtained the second class medical device registration certificate in People’s Republic of China (PRC). Eston medical bedside nursing robot is mainly suitable for disabled, paralyzed and early ICU patients. It can move the knees and hips of lower limbs, prevent and improve joint adhesion, and also train the muscles of lower limbs in several functional modules such as stretching, strength and motion control.
other
Anstalai Pharmaceutical Group released the main results of the Phase III MOONLIGHT 3 clinical trial in women in Chinese mainland, aiming at evaluating the long-term safety and tolerability of Fezolinetant, a non-hormonal oral drug under study, in the treatment of moderate and severe vasomotor symptoms (VMS) related to menopause. VMS is a common symptom of menopause, characterized by hot flashes and/or night sweats. Fezolinetant is an oral non-hormonal drug under clinical development, which is used to treat moderate and severe VMS related to menopause.